These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 6813444)

  • 1. Carnitine deficiency and hyperammonemia associated with valproic acid therapy.
    Ohtani Y; Endo F; Matsuda I
    J Pediatr; 1982 Nov; 101(5):782-5. PubMed ID: 6813444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs.
    Verrotti A; Greco R; Morgese G; Chiarelli F
    Int J Clin Lab Res; 1999; 29(1):36-40. PubMed ID: 10356662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs.
    Thom H; Carter PE; Cole GF; Stevenson KL
    Dev Med Child Neurol; 1991 Sep; 33(9):795-802. PubMed ID: 1936631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The problems of valproate therapy in severely handicapped children--valproate induced hyperammonemia and hypocarnitinemia].
    Matsui K; Iwamoto H; Ohtsuki N; Kobayashi T; Miyake S; Yamada M
    No To Hattatsu; 1991 Jan; 23(1):32-8. PubMed ID: 1825272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of carnitine supplementation during valproic acid therapy.
    Raskind JY; El-Chaar GM
    Ann Pharmacother; 2000 May; 34(5):630-8. PubMed ID: 10852092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of carnitine supplementation in valproate-induced hyperammonaemia.
    Böhles H; Sewell AC; Wenzel D
    Acta Paediatr; 1996 Apr; 85(4):446-9. PubMed ID: 8740302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum carnitine, beta-hydroxybutyrate and ammonia levels during valproic acid therapy.
    Toksoy HB; Tanzer FN; Atalay A
    Turk J Pediatr; 1995; 37(1):25-9. PubMed ID: 7732605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carnitine deficiency during valproic acid treatment.
    Van Wouwe JP
    Int J Vitam Nutr Res; 1995; 65(3):211-4. PubMed ID: 8830002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy.
    Matsuda I; Ohtani Y; Ninomiya N
    J Pediatr; 1986 Jul; 109(1):131-4. PubMed ID: 3088240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
    Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
    Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymptomatic hyperammonemia in children treated with valproic acid.
    Altunbaşak S; Baytok V; Tasouji M; Hergüner O; Burgut R; Kayrin L
    J Child Neurol; 1997 Oct; 12(7):461-3. PubMed ID: 9373804
    [No Abstract]   [Full Text] [Related]  

  • 14. Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia.
    Maldonado C; Guevara N; Queijo C; González R; Fagiolino P; Vázquez M
    Biomed Res Int; 2016; 2016():2920108. PubMed ID: 26998483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case report of valproate encephalopathy].
    Miyamoto T; Miyamoto M; Hirata K; Katayama S
    Rinsho Shinkeigaku; 1999 Oct; 39(10):1075-7. PubMed ID: 10655774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine.
    Gidal BE; Inglese CM; Meyer JF; Pitterle ME; Antonopolous J; Rust RS
    Pediatr Neurol; 1997 May; 16(4):301-5. PubMed ID: 9258962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproate-associated hyperammonemia and DL-carnitine supplement.
    Komatsu M; Kodama S; Yokoyama S; Konishi H; Tanaka K; Momota K; Wada H; Matsuo T
    Kobe J Med Sci; 1987 Jun; 33(3):81-7. PubMed ID: 2959815
    [No Abstract]   [Full Text] [Related]  

  • 18. Secondary carnitine deficiency in handicapped patients receiving valproic acid and/or elemental diet.
    Igarashi N; Sato T; Kyouya S
    Acta Paediatr Jpn; 1990 Apr; 32(2):139-45. PubMed ID: 2143048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carnitine deficiency associated with anticonvulsant therapy.
    Rodriguez-Segade S; de la Peña CA; Tutor JC; Paz JM; Fernandez MP; Rozas I; Del Río R
    Clin Chim Acta; 1989 May; 181(2):175-81. PubMed ID: 2500272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The decreased level of plasma carnitine in patients with epilepsy].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):106-110. PubMed ID: 28745680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.